Oncology Medical News about cervical cancer risk;CD83

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

CD83 polymorphisms and cervical cancer risk
Gynecologic Oncology, 06/30/09

Yu KJ et al. - In a study to replicate a recent study that reported an association between specific SNPs on CD83 and cervical cancer and to explore whether effects varied by age, clinical stage (in situ vs invasive), and histology (squamous carcinomas vs adenocarcinomas), an association between CD83 polymorphisms and cervical cancer was confirmed, suggesting the possibility that CD83-disease associations might be heterogenous by tumor histology.

Methods

The association between SNPs on CD83 and cervical cancer was evaluated in a multicenter case-control study (263 cases, 307 controls), focusing on the 5 SNPs (RS9296925, RS853360, RS9230, RS9370729, RS750749) previously found to be associated with cervical cancer.
Data were pooled from the Eastern US (263 cases) with those from the original report (377 cases) to assess the effects of CD83 on the age at diagnosis, disease stage, and histology.
Risk estimates (ORs) and 95% confidence intervals were estimated using logistic regression; trend tests were performed under an additive model.

Results

Consistent with the original report, carriers of CT or CC genotypes for 1 of 5 CD83 SNPs evaluated (rs750749) demonstrated a 30% and 50% reduction in disease risk, relative to carriers of the more common TT genotype.
2 additional SNPs also resulted in consistent findings (rs9296925 and rs9370729), although effects observed did not reach statistical significance at the 0.05 level.
Pooled evaluation of cases from the 2 aforementioned studies suggested differences in distribution of susceptibility alleles by histology; adenocarcinoma cases were more likely to be carriers of the susceptibility alleles for SNP rs9370729 and SNP rs750749.
No differences were observed in age or stage of diagnosis of carriers for CD83 susceptibility alleles relative to non-carriers.

<< Previous
Platin-based exclusive chemotherapy for selected patients with...

Next >>
Mental status changes after hematopoietic stem cell...